Drug Profile
APX 1004
Alternative Names: APX-1004; APX-1004FLatest Information Update: 17 Oct 2023
Price :
$50
*
At a glance
- Originator AptaBio Therapeutics
- Class Eye disorder therapies; Small molecules
- Mechanism of Action NADPH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Wet age-related macular degeneration
- Phase I Diabetic retinopathy
Most Recent Events
- 16 Oct 2023 APX 1004 is still in phase I trials for Diabetic-retinopathy in South Korea (AptaBio Therapeutics pipeline, October 2023)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Diabetic-retinopathy in South Korea
- 21 Jun 2022 AptaBio Therapeutics plans a phase II trial in Diabetic retinopathy in the year 2023 (AptaBio Therapeutics pipeline, June 2022)